Penumbra came into this Q3 2026 earnings print priced for perfection, with the stock near US$319 and a rich 80.1x P/E that already reflected big hopes for its medical devices pipeline. The latest quarter delivered solid headline results, with revenue at US$410.1 million and basic earnings per share of US$1.07, yet the share price slipped about 0.9% on the day. That small pullback points to a gap between expectations and results. The business is still reporting healthy sales and profit, while investors are starting to question how much upside is left at this valuation.
Love Penumbra's healthy sales and earnings but uneasy about paying an 80.1x P/E for that growth story? Consider a curated 29 high quality undervalued stocks if you want businesses with steadier valuations paired with strong fundamentals.
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$410.1 million vs. US$354.7 million (up about 15.6%)
-
Net Income, excl. extra items (Q3 2026 vs. Q3 2025):US$42.3 million vs. US$45.9 million (down about 7.8%)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$1.07 vs. US$1.17 (down about 8.5%)
-
Trailing Twelve Month Net Profit Margin (latest vs. prior year):10.1% vs. 12.3% (compressed by about 2.2 percentage points)
Penumbra's profit margin slipped even as revenue kept climbing. Ask Charlie what makes Penumbra worth an 80x earnings tag .
Penumbra's Bull Case Hinges On Execution Milestones
The bullish view rests on Penumbra turning clinical and manufacturing plans into tangible scale, not just incremental device sales.
"The main factor that has to go right is that Penumbra maintains strong execution across thrombectomy, embolization and manufacturing expansion, while integrating smoothly into Boston Scientific following the planned acquisition closing in 2026."
Q3 revenue of US$410.1 million, with strong U.S. venous thromboembolism and neuro growth, supports the idea that thrombectomy and embolization platforms are gaining real commercial traction. The first ever FDA clearance for Lightning CAVT in deep vein thrombosis and fresh pulmonary embolism data mark concrete clinical milestones. The limited Class II RED 62 recall and margin compression indicate that manufacturing and cost execution still have work to do before the broader thesis is fully proven.
The price and this Narrative do not agree. → Uncover what this Narrative says Penumbra is actually worth .
Penumbra Bear Case: Margin Strain And Deal Fog Linger
Bearish investors worry that Penumbra's broader product footprint and deal journey could hurt execution rather than help it.
"While Penumbra is advancing multiple thrombectomy and embolization platforms, including THUNDERBOLT, Lightning CAVT for DVT and expanded stroke studies, this wider product footprint increases exposure to regulatory reviews, device performance questions and post clearance safety actions such as the Class II RED 62 catheter recall."
Q3 shows elements of that concern. Net income and EPS both moved lower year on year, and trailing net margin compressed to 10.1%. The Class II RED 62 recall stayed limited, yet management withheld full year guidance because Boston Scientific deal costs are hard to frame. This leaves the integration and margin story short of the clarity bears are asking for.
Hunt For Mispriced Growth Stories
Penumbra shows how a strong business can still face valuation questions after earnings. The real opportunity sits in finding stocks that could be undervalued before the market adjusts.
-
Company 1 - 19% below our estimate - expands a teahouse and membership network as overseas order volumes reshape store mix and franchise economics.
-
Company 2 - 38% below our estimate - builds protective film capacity so higher margin installation and dealership channels can absorb rising demand across more vehicle and surface categories.
-
Company 3 - 47% below our estimate - turns heavy AI infrastructure spending into ad tools and messaging formats that reshape how marketers target and convert commercial activity.
That is three of the list. See all 29 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PEN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
